Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research – Anti Allergy Agents

Volume 3

eBook: US $99 Special Offer (PDF + Printed Copy): US $168
Printed Copy: US $119
Library License: US $396
ISSN: 2452-3194 (Print)
ISSN: 2214-6938 (Online)
ISBN: 978-1-68108-338-4 (Print)
ISBN: 978-1-68108-337-7 (Online)
Year of Publication: 2018
DOI: 10.2174/97816810833771180301


Frontiers in Clinical Drug Research - Anti-Allergy Agents is a book series comprising of a selection of updated review articles relevant to the recent development of pharmacological agents used for the treatment of allergies. The scope of the reviews includes clinical trials of anti-inflammatory and anti-allergic drugs, drug delivery strategies used to treat specific allergies (such as inflammation, asthma and dermatological allergies), lifestyle dependent modes of therapies and the immunological or metabolic mechanisms that are of interest to researchers as targets for new drugs.

The third volume of this series brings 5 reviews which cover the following topics: H1 receptor selectivity, chronic spontaneous urticaria therapy, smooth muscle cell Ca2+ signaling pathway targeting for asthma therapy, allergic rhinitis and endosomal toll-like receptors.

Frontiers in Clinical Drug Research - Anti-Allergy Agents will be of interest to immunologists and drug discovery researchers interested in anti-allergic drug therapy as the series provides relevant cutting edge reviews written by experts in this rapidly expanding field.


Frontiers in Clinical Drug Research - Anti Allergy Agents (Volume 3) comprises five comprehensive chapters on various treatment strategies for allergic conditions. In chapter 1, Cundell and Mickle focus on the existing different generations of drugs and the development of more potent anti-histamines. In the second chapter, Gonzalez-Estrada and Fernandez discuss the common drugs used for managing Chronic Spontaneous Urticaria, their side effects, and monitoring parameters. Both Ca2+ dynamics and Ca2+ sensitization are responsible for alterations in contractility in airway smooth muscle cells that lead to conditions of asthma and chronic obstructive pulmonary disease (COPD). Hiroaki Kume in chapter 3 of this book explain that the Ca2+ dynamics and Ca2+ sensitization may be the therapeutic approaches for treating asthma and COPD, and research in these areas may provide novel strategies for the development of bronchodilators for these diseases that will be effective for both bronchoconstriction and airway inflammation. In the next chapter Cingi et al. review the effects of Allergic Rhinitis on communication skills mainly in three categories: physiological, psychological and behavioral. In the last chapter, Bajpai et al. present the role of Endosomal Toll-like Receptors in inflammation and related diseases. They focus on the structural features of Toll-like Receptors, specific ligands, intracellular signaling and the role of Endosomal TLRs in the aggravation of diseases.

I hope that this volume will be of great interest to the scientific community and will play a vital role in the development of more effective therapeutic agents to combat various pulmonary ailments.

I would like to thank all the authors and the excellent team of Bentham Science Publishers, especially Dr. Faryal Sami, Mr. Shehzad Naqvi and Mr. Mahmood Alam for their support and hardwork.

Prof. Atta-ur-Rahman, FRS
Honorary Life Fellow,
Kings College,
University of Cambridge,


.The NLRP3 Inflammasome: An Attentive Arbiter of Inflammatory Response.
.Natural Immunomodulators: Promising Therapy for Disease Management.
.Herbal Immunity Boosters Against COVID-19.
.Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases.